Turnstone Biologics Future Growth
Future criteria checks 0/6
Turnstone Biologics's revenue and earnings are forecast to decline at 94.1% and 18.9% per annum respectively while EPS is expected to grow by 5.9% per annum.
Key information
-18.9%
Earnings growth rate
5.9%
EPS growth rate
| Biotechs earnings growth | 24.4% |
| Revenue growth rate | -94.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 28 Mar 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -121 | N/A | N/A | 2 |
| 12/31/2025 | N/A | -104 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -74 | N/A | N/A | 3 |
| 12/31/2023 | 19 | -55 | -67 | -66 | N/A |
| 9/30/2023 | 30 | -52 | -72 | -70 | N/A |
| 6/30/2023 | 40 | -51 | -67 | -63 | N/A |
| 3/31/2023 | 82 | -18 | -77 | -72 | N/A |
| 12/31/2022 | 73 | -31 | -76 | -71 | N/A |
| 12/31/2021 | 101 | 3 | -49 | -46 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TSBX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TSBX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TSBX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TSBX is forecast to have no revenue next year.
High Growth Revenue: TSBX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TSBX's Return on Equity is forecast to be high in 3 years time